Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
456.69
-4.13 (-0.90%)
At close: Mar 6, 2026, 4:00 PM EST
454.12
-2.57 (-0.56%)
After-hours: Mar 6, 2026, 7:52 PM EST
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 6,400 employees as of December 31, 2025. The number of employees increased by 300 or 4.92% compared to the previous year.
Employees
6,400
Change (1Y)
300
Growth (1Y)
4.92%
Revenue / Employee
$1,875,203
Profits / Employee
$617,688
Market Cap
116.01B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6,400 | 300 | 4.92% |
| Dec 31, 2024 | 6,100 | 700 | 12.96% |
| Dec 31, 2023 | 5,400 | 600 | 12.50% |
| Dec 31, 2022 | 4,800 | 900 | 23.08% |
| Dec 31, 2021 | 3,900 | 500 | 14.71% |
| Dec 31, 2020 | 3,400 | 400 | 13.33% |
| Dec 31, 2019 | 3,000 | 500 | 20.00% |
| Dec 31, 2018 | 2,500 | 200 | 8.70% |
| Dec 31, 2017 | 2,300 | 150 | 6.98% |
| Dec 31, 2016 | 2,150 | 200 | 10.26% |
| Dec 31, 2015 | 1,950 | 120 | 6.56% |
| Dec 31, 2014 | 1,830 | 30 | 1.67% |
| Dec 31, 2013 | 1,800 | -400 | -18.18% |
| Dec 31, 2012 | 2,200 | 200 | 10.00% |
| Dec 31, 2011 | 2,000 | 309 | 18.27% |
| Dec 31, 2010 | 1,691 | 259 | 18.09% |
| Dec 31, 2009 | 1,432 | 99 | 7.43% |
| Dec 31, 2008 | 1,333 | 183 | 15.91% |
| Dec 31, 2007 | 1,150 | 188 | 19.54% |
| Dec 31, 2006 | 962 | 149 | 18.33% |
| Dec 31, 2005 | 813 | 77 | 10.46% |
| Dec 31, 2004 | 736 | 12 | 1.66% |
| Dec 31, 2003 | 724 | -256 | -26.12% |
| Dec 31, 2002 | 980 | -20 | -2.00% |
| Dec 31, 2001 | 1,000 | 545 | 119.78% |
| Dec 31, 2000 | 455 | 102 | 28.90% |
| Dec 31, 1999 | 353 | 13 | 3.82% |
| Dec 31, 1998 | 340 | 120 | 54.55% |
| Dec 31, 1997 | 220 | 42 | 23.60% |
| Dec 31, 1996 | 178 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 6,772 |
| Moderna | 4,700 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Insmed | 1,664 |
| argenx SE | 1,599 |
VRTX News
- 1 day ago - Vertex to Participate in Upcoming March Investor Conferences - Business Wire
- 1 day ago - Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures - Business Wire
- 3 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 6 days ago - 10 Best CEFs This Month: Average Yield Of 9.7% (February 2026) - Seeking Alpha
- 16 days ago - Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade) - Seeking Alpha
- 17 days ago - Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3 - Business Wire
- 22 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments - Reuters